VANCOUVER, B.C., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that the United States Patent & Trademark Office (USPTO) has recently issued two key patents expanding its intellectual property portfolio: one covers its lipid nanoparticle (LNP) delivery technology (U.S. Patent No. 8,058,069), and the other covers the chemical modification of siRNA to mitigate immune stimulation (U.S. Patent No. 8,101,741).
